Direct-to-store model (delivering drugs directly to each retailer’s stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007 ...

The Global Healthcare Cold Chain Logistics Market is poised for substantial growth, with projections indicating an increase to $29.72 billion by 2033. This report provides an in-d ...

Dalfen Industrial has bolstered its holdings with the off-market acquisition of a premier industrial property strategically ...

In response to the escalating congestion crisis at the Colombo Port, a coalition of 29 leading chambers of commerce, trade, maritime and logistics associations has proposed a comprehensive action plan ...

Cardinal Health (NYSE:CAH) reported its second-quarter earnings for fiscal year 2024, surpassing analyst expectations with an ...

Q2 2025 Earnings Call Transcript January 30, 2025 Cardinal Health, Inc. beats earnings expectations. Reported EPS is $1.93, ...

Cardinal's pharmaceutical and specialty solutions segment distributes branded, generic, and specialty drugs and over-the-counter healthcare and consumer products. Cardinal plays a central role in the ...

Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its ...

Cardinal Health's second-quarter fiscal 2025 results benefit from solid Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.

Cardinal Health has reported second quarter revenue for its “other” businesses, which includes at-Home Solutions, increased 13% to $1.3 billion.

Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.

Revenue decreased 4% to $55.3 billion; revenue increased 16% excluding the impact of the previously communicated large customer contract expiration GAAP1 operating ...